AU2001238595A1
(en)
*
|
2000-02-22 |
2001-09-03 |
Shearwater Corporation |
N-maleimidyl polymer derivatives
|
CA2404737C
(en)
*
|
2000-04-03 |
2010-06-29 |
Santen Pharmaceutical Co., Ltd. |
Drug delivering substance containing polyalkylene glycol and phospholipid covalently bonded to drug
|
DE60117849T2
(en)
*
|
2000-10-23 |
2006-09-21 |
Genetics Institute, LLC, Cambridge |
Acid-sensitive Isotope-coded Extractor (Alice) in mass spectrometry analysis
|
JP4123856B2
(en)
*
|
2001-07-31 |
2008-07-23 |
日油株式会社 |
Bio-related substance modifier and method for producing polyoxyalkylene derivative
|
CN1318093C
(en)
*
|
2001-09-28 |
2007-05-30 |
参天制药株式会社 |
Injections for eye tissue containing drug bound to polyethylene glycol
|
CN100343305C
(en)
*
|
2002-12-31 |
2007-10-17 |
尼克塔治疗亚拉巴马公司 |
Maleamic acid polymer derivatives and their bioconjugates
|
MXPA05007151A
(en)
*
|
2002-12-31 |
2005-09-21 |
Nektar Therapeutics Al Corp |
Hydrolytically stable maleimide-terminated polymers.
|
JP4490369B2
(en)
|
2002-12-31 |
2010-06-23 |
ネクター セラピューティクス アラバマ,コーポレイション |
Maleamic acid polymer derivatives and biological complexes thereof
|
US7432331B2
(en)
*
|
2002-12-31 |
2008-10-07 |
Nektar Therapeutics Al, Corporation |
Hydrolytically stable maleimide-terminated polymers
|
MXPA05009169A
(en)
|
2003-02-26 |
2005-11-17 |
Nektar Therapeutics Al Corp |
Polymer-factor viii moiety conjugates.
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
PL1603541T5
(en)
|
2003-03-05 |
2013-06-28 |
Halozyme Inc |
SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF
|
WO2004091517A2
(en)
|
2003-04-15 |
2004-10-28 |
Smithkline Beecham Corporation |
Conjugates comprising human il-18 and substitution mutants thereof
|
SI1656410T1
(en)
*
|
2003-07-22 |
2010-07-30 |
Nektar Therapeutics |
Method for preparing functionalized polymers from polymer alcohols
|
DK1675622T3
(en)
*
|
2003-09-17 |
2017-09-18 |
Nektar Therapeutics |
Multi-arm polymer preparations
|
US8394365B2
(en)
|
2003-09-17 |
2013-03-12 |
Nektar Therapeutics |
Multi-arm polymer prodrugs
|
US7230068B2
(en)
|
2003-10-09 |
2007-06-12 |
Ambrx, Inc. |
Polymer derivatives
|
US7605120B2
(en)
*
|
2003-10-22 |
2009-10-20 |
Amgen Inc. |
Antagonists of the brandykinin B1 receptor
|
CN100415801C
(en)
*
|
2003-10-28 |
2008-09-03 |
北京键凯科技有限公司 |
Polyethylene glycol amino acid N-internal ring carbonyl anhydride active derivatives, and medicinal bonding compound and gel thereof
|
WO2005056636A2
(en)
*
|
2003-12-03 |
2005-06-23 |
Nektar Therapeutics Al, Corporation |
Method of preparing maleimide functionalized polymers
|
US20050208671A1
(en)
*
|
2003-12-26 |
2005-09-22 |
Nof Corporation |
Method of analyzing the ratio of activation of terminals of polyoxyalkylene derivatives
|
JP4543917B2
(en)
*
|
2003-12-26 |
2010-09-15 |
日油株式会社 |
Method for analyzing terminal activation rate of polyoxyalkylene derivative
|
BRPI0507169A
(en)
|
2004-02-02 |
2007-06-26 |
Ambrx Inc |
modified human growth hormone polypeptides and their uses
|
US6887952B1
(en)
*
|
2004-02-12 |
2005-05-03 |
Biosite, Inc. |
N-aryl-carbamic acid ester-derived and valeric acid ester-derived cross-linkers and conjugates, and methods for their synthesis and use
|
WO2005089805A2
(en)
*
|
2004-03-15 |
2005-09-29 |
Nektar Therapeutics Al, Corporation |
Polymer-based compositions and conjugates of hiv entry inhibitors
|
JP2008503217A
(en)
|
2004-06-18 |
2008-02-07 |
アンブレツクス・インコーポレイテツド |
Novel antigen-binding polypeptides and their use
|
US7456151B2
(en)
|
2004-07-14 |
2008-11-25 |
University Of Utah Research Foundation |
Promoting angiogenesis with netrin1 polypeptides
|
CN100420671C
(en)
*
|
2004-08-12 |
2008-09-24 |
董树有 |
Maleimide derivative and its preparation method and uses
|
US7317059B2
(en)
*
|
2004-09-24 |
2008-01-08 |
Fuji Xerox Co., Ltd. |
Ligand immobilization support
|
AU2005319518B2
(en)
|
2004-12-22 |
2010-09-09 |
Ambrx, Inc. |
Compositions of aminoacyl-tRNA synthetase and uses thereof
|
US7816320B2
(en)
|
2004-12-22 |
2010-10-19 |
Ambrx, Inc. |
Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35
|
NZ555206A
(en)
|
2004-12-22 |
2010-09-30 |
Ambrx Inc |
Methods for expression and purification of recombinant human growth hormone
|
KR20070090023A
(en)
|
2004-12-22 |
2007-09-04 |
암브룩스, 인코포레이티드 |
Modified human growth hormone
|
WO2006110776A2
(en)
|
2005-04-12 |
2006-10-19 |
Nektar Therapeutics Al, Corporation |
Polyethylene glycol cojugates of antimicrobial agents
|
US7833979B2
(en)
*
|
2005-04-22 |
2010-11-16 |
Amgen Inc. |
Toxin peptide therapeutic agents
|
US20100135959A1
(en)
|
2005-06-03 |
2010-06-03 |
Ambrx, Inc. |
Human Interferon Molecules and Their Uses
|
WO2007011802A1
(en)
*
|
2005-07-18 |
2007-01-25 |
Nektar Therapeutics Al, Corporation |
Method for preparing branched functionalized polymers using branched polyol cores
|
ES2341285T3
(en)
*
|
2005-07-19 |
2010-06-17 |
Nektar Therapeutics |
METHOD TO PREPARE POLYMERIC MALEIMIDS.
|
KR100735784B1
(en)
*
|
2005-07-20 |
2007-07-06 |
재단법인 목암생명공학연구소 |
Mutant of granulocyte-colony stimulating factorG-CSF and chemically conjugated polypeptide thereof
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
ATE425204T1
(en)
*
|
2005-08-26 |
2009-03-15 |
Novo Nordisk As |
METHOD FOR MODIFYING A MACROMOLECULAR SYSTEM
|
US20080171696A1
(en)
*
|
2005-10-21 |
2008-07-17 |
Avigenics, Inc. |
Pharmacodynamically enhanced therapeutic proteins
|
US20070092486A1
(en)
*
|
2005-10-21 |
2007-04-26 |
Avigenics, Inc. |
Glycolated and glycosylated poultry derived therapeutic proteins
|
US8168592B2
(en)
*
|
2005-10-21 |
2012-05-01 |
Amgen Inc. |
CGRP peptide antagonists and conjugates
|
EP2339014B1
(en)
|
2005-11-16 |
2015-05-27 |
Ambrx, Inc. |
Methods and compositions comprising non-natural amino acids
|
JP2009518519A
(en)
*
|
2005-12-06 |
2009-05-07 |
タイコ ヘルスケア グループ リミテッド パートナーシップ |
Carbodiimide crosslinking of functionalized polyethylene glycol
|
JP5096363B2
(en)
|
2005-12-16 |
2012-12-12 |
ネクター セラピューティックス |
GLP-1 polymer complex
|
JP2009533347A
(en)
|
2006-04-07 |
2009-09-17 |
ネクター セラピューティックス エイエル,コーポレイション |
Anti-TNFα antibody complex
|
AU2007267798A1
(en)
*
|
2006-05-26 |
2007-12-06 |
Ipsen Pharma S.A.S. |
Methods for site-specific pegylation
|
MX2009002460A
(en)
|
2006-09-08 |
2009-03-20 |
Ambrx Inc |
Hybrid suppressor trna for vertebrate cells.
|
US8420792B2
(en)
|
2006-09-08 |
2013-04-16 |
Ambrx, Inc. |
Suppressor tRNA transcription in vertebrate cells
|
EP2615108B1
(en)
|
2006-09-08 |
2016-10-26 |
Ambrx, Inc. |
Modified human plasma polypeptide or fc scaffolds and thier uses
|
WO2008051383A2
(en)
*
|
2006-10-19 |
2008-05-02 |
Amgen Inc. |
Use of alcohol co-solvents to improve pegylation reaction yields
|
EP2081602A2
(en)
*
|
2006-10-25 |
2009-07-29 |
Amgen Inc. |
Toxin peptide therapeutic agents
|
CN101583380B
(en)
|
2006-11-30 |
2013-07-10 |
尼克塔治疗公司 |
Method for preparing a polymer conjugate
|
EP1955712A1
(en)
|
2007-02-09 |
2008-08-13 |
Scil proteins GmbH |
Multimeric conjugate
|
ES2385114T3
(en)
|
2007-03-30 |
2012-07-18 |
Ambrx, Inc. |
Modified FGF-21 polypeptides and their uses
|
US8114630B2
(en)
|
2007-05-02 |
2012-02-14 |
Ambrx, Inc. |
Modified interferon beta polypeptides and their uses
|
CA2687141C
(en)
|
2007-05-22 |
2014-04-01 |
Amgen Inc. |
Compositions and methods for producing bioactive fusion proteins
|
KR100771100B1
(en)
*
|
2007-07-18 |
2007-10-29 |
아이디비켐(주) |
A new preparing method of methoxypolyethyleneglycol ethylmaleimide
|
NZ603812A
(en)
|
2007-11-20 |
2014-06-27 |
Ambrx Inc |
Modified insulin polypeptides and their uses
|
CN101939443B
(en)
|
2008-02-08 |
2014-01-29 |
Ambrx公司 |
Modified leptin polypeptides and their uses
|
TWI395593B
(en)
|
2008-03-06 |
2013-05-11 |
Halozyme Inc |
In vivo temporal control of activatable matrix-degrading enzymes
|
SG187427A1
(en)
|
2008-04-14 |
2013-02-28 |
Halozyme Inc |
Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
|
TWI394580B
(en)
|
2008-04-28 |
2013-05-01 |
Halozyme Inc |
Super fast-acting insulin compositions
|
KR101001734B1
(en)
|
2008-06-05 |
2010-12-15 |
아이디비켐(주) |
A New Analyzing Method of Methoxypolyethyleneglycol Ethylmaleimide
|
TWI451876B
(en)
|
2008-06-13 |
2014-09-11 |
Lilly Co Eli |
Pegylated insulin lispro compounds
|
UA103774C2
(en)
|
2008-07-23 |
2013-11-25 |
Амбркс, Інк. |
Modified bovine g-csf polypeptides and their uses
|
KR101671537B1
(en)
|
2008-08-11 |
2016-11-01 |
넥타르 테라퓨틱스 |
Multi-arm polymeric alkanoate Conjugates
|
US20110171166A1
(en)
*
|
2008-09-19 |
2011-07-14 |
Nektar Therapeutics |
Polymer conjugates of osteocalcin peptides
|
EP2344199A1
(en)
*
|
2008-09-19 |
2011-07-20 |
Nektar Therapeutics |
Polymer conjugates of thymosin alpha 1 peptides
|
EP2340045B1
(en)
*
|
2008-09-19 |
2017-04-12 |
Nektar Therapeutics |
Polymer conjugates of protegrin peptides
|
EP2340046A2
(en)
*
|
2008-09-19 |
2011-07-06 |
Nektar Therapeutics |
Polymer conjugates of ziconotide peptides
|
US20110171164A1
(en)
*
|
2008-09-19 |
2011-07-14 |
Nektar Therapeutics |
Polymer conjugates of glp-2-like peptides
|
EP2334333A1
(en)
*
|
2008-09-19 |
2011-06-22 |
Nektar Therapeutics |
Polymer conjugates of v681-like peptides
|
EP2334338A2
(en)
*
|
2008-09-19 |
2011-06-22 |
Nektar Therapeutics |
Polymer conjugates of c-peptides
|
EP2898900B1
(en)
|
2008-09-19 |
2017-11-15 |
Nektar Therapeutics |
Polymer conjugates of ziconotide
|
WO2010033216A1
(en)
|
2008-09-19 |
2010-03-25 |
Nektar Therapeutics |
Polymer conjugates of nesiritide peptides
|
WO2010033223A1
(en)
*
|
2008-09-19 |
2010-03-25 |
Nektar Therapeutics |
Polymer conjugates of opioid growth factor peptides
|
EP2340047A1
(en)
*
|
2008-09-19 |
2011-07-06 |
Nektar Therapeutics |
Polymer conjugates of kiss1 peptides
|
WO2010033215A2
(en)
*
|
2008-09-19 |
2010-03-25 |
Nektar Therapeutics |
Polymer conjugates of aod-like peptides
|
WO2010033220A2
(en)
*
|
2008-09-19 |
2010-03-25 |
Nektar Therapeutics |
Modified therapeutics peptides, methods of their preparation and use
|
DK2337846T3
(en)
|
2008-09-26 |
2018-03-12 |
Ambrx Inc |
NON-NATURAL AMINO ACID REPLICATION DEPENDENT MICROORGANISMS AND VACCINES
|
WO2010036964A2
(en)
|
2008-09-26 |
2010-04-01 |
Ambrx Inc. |
Modified animal erythropoietin polypeptides and their uses
|
SG172064A1
(en)
|
2008-12-09 |
2011-07-28 |
Halozyme Inc |
Extended soluble ph20 polypeptides and uses thereof
|
GB0823309D0
(en)
*
|
2008-12-19 |
2009-01-28 |
Univ Bath |
Functionalising reagents and their uses
|
US20110318322A1
(en)
|
2009-01-12 |
2011-12-29 |
Nektar Therapeutics |
Conjugates of a Lysosomal Enzyme Moiety and a Water Soluble Polymer
|
EA026112B1
(en)
|
2009-09-17 |
2017-03-31 |
Бакстер Хелскэа, С.А. |
Stable composition comprising hyaluronidase and immunoglobulin, and methods of use thereof
|
CN102612674B
(en)
|
2009-11-17 |
2015-05-27 |
苹果公司 |
Wireless power utilization in a local computing environment
|
US20110136727A1
(en)
*
|
2009-11-20 |
2011-06-09 |
Sergei Svarovsky |
Compositions and methods for rapid selection of pathogen binding agents
|
NZ600361A
(en)
|
2009-12-21 |
2014-06-27 |
Ambrx Inc |
Modified bovine somatotropin polypeptides and their uses
|
CN102666578A
(en)
|
2009-12-21 |
2012-09-12 |
Ambrx公司 |
Modified porcine somatotropin polypeptides and their uses
|
KR20130115086A
(en)
|
2010-05-17 |
2013-10-21 |
세빅스 인코포레이티드 |
Pegylated c-peptide
|
US9878046B2
(en)
|
2010-07-20 |
2018-01-30 |
Halozyme, Inc. |
Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects
|
EP3578205A1
(en)
|
2010-08-06 |
2019-12-11 |
ModernaTX, Inc. |
A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
|
KR101963460B1
(en)
|
2010-08-17 |
2019-03-28 |
암브룩스, 인코포레이티드 |
Modified relaxin polypeptides and their uses
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
AR083006A1
(en)
|
2010-09-23 |
2013-01-23 |
Lilly Co Eli |
FORMULATIONS FOR THE STIMULATING FACTOR OF COLONIES OF GRANULOCITS (G-CSF) BOVINE AND VARIANTS OF THE SAME
|
EP2857499A1
(en)
|
2010-10-01 |
2015-04-08 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
WO2012054822A1
(en)
|
2010-10-22 |
2012-04-26 |
Nektar Therapeutics |
Pharmacologically active polymer-glp-1 conjugates
|
PT2637694T
(en)
|
2010-11-12 |
2021-05-05 |
Nektar Therapeutics |
Conjugates of an il-2 moiety and a polymer
|
US10894087B2
(en)
|
2010-12-22 |
2021-01-19 |
Nektar Therapeutics |
Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
|
WO2012088422A1
(en)
|
2010-12-22 |
2012-06-28 |
Nektar Therapeutics |
Multi-arm polymeric prodrug conjugates of taxane-based compounds
|
ES2634669T3
(en)
|
2011-02-08 |
2017-09-28 |
Halozyme, Inc. |
Composition and lipid formulation of a hyaluronan degradation enzyme and use thereof for the treatment of benign prostatic hyperplasia
|
US9340590B2
(en)
|
2011-03-16 |
2016-05-17 |
Amgen Inc. |
Potent and selective inhibitors of NaV1.3 and NaV1.7
|
EP2691101A2
(en)
|
2011-03-31 |
2014-02-05 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
WO2012166555A1
(en)
|
2011-05-27 |
2012-12-06 |
Nektar Therapeutics |
Water - soluble polymer - linked binding moiety and drug compounds
|
US8815226B2
(en)
|
2011-06-10 |
2014-08-26 |
Mersana Therapeutics, Inc. |
Protein-polymer-drug conjugates
|
WO2012171020A1
(en)
|
2011-06-10 |
2012-12-13 |
Mersana Therapeutics, Inc. |
Protein-polymer-drug conjugates
|
US20130011378A1
(en)
|
2011-06-17 |
2013-01-10 |
Tzung-Horng Yang |
Stable formulations of a hyaluronan-degrading enzyme
|
WO2012174480A2
(en)
|
2011-06-17 |
2012-12-20 |
Halozyme, Inc. |
Continuous subcutaneous insulin infusion methods with a hyaluronan degrading enzyme
|
WO2013020079A2
(en)
|
2011-08-04 |
2013-02-07 |
Nektar Therapeutics |
Conjugates of an il-11 moiety and a polymer
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
US20130071394A1
(en)
|
2011-09-16 |
2013-03-21 |
John K. Troyer |
Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use
|
SG10201602654SA
(en)
|
2011-10-03 |
2016-05-30 |
Moderna Therapeutics Inc |
Modified nucleosides,nucleotides,and nucleic acids,and uses thereof
|
WO2013063155A2
(en)
|
2011-10-24 |
2013-05-02 |
Halozyme, Inc. |
Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
|
CN104220086A
(en)
|
2011-11-17 |
2014-12-17 |
塞比克斯股份公司 |
PEGylated C-peptide
|
CA3018046A1
(en)
|
2011-12-16 |
2013-06-20 |
Moderna Therapeutics, Inc. |
Modified nucleoside, nucleotide, and nucleic acid compositions
|
SI3130347T1
(en)
|
2011-12-30 |
2020-02-28 |
Halozyme, Inc. |
Ph20 polypeptide variants, formulations and uses thereof
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
AU2013243950A1
(en)
|
2012-04-02 |
2014-10-30 |
Moderna Therapeutics, Inc. |
Modified polynucleotides
|
US9303079B2
(en)
|
2012-04-02 |
2016-04-05 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
MX360092B
(en)
|
2012-04-04 |
2018-10-19 |
Halozyme Inc |
Combination therapy with an anti - hyaluronan agent and a tumor - targeted taxane.
|
EP2859017B1
(en)
|
2012-06-08 |
2019-02-20 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
US9732161B2
(en)
|
2012-06-26 |
2017-08-15 |
Sutro Biopharma, Inc. |
Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
|
KR102182800B1
(en)
|
2012-08-31 |
2020-11-25 |
서트로 바이오파마, 인크. |
Modified amino acids comprising an azido group
|
WO2014058359A1
(en)
*
|
2012-10-09 |
2014-04-17 |
Yuji Teramura |
Method of coating and encapsulation of cells and cell aggregates with thick and stable polymer membrane
|
US9278124B2
(en)
|
2012-10-16 |
2016-03-08 |
Halozyme, Inc. |
Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
|
PT2922554T
(en)
|
2012-11-26 |
2022-06-28 |
Modernatx Inc |
Terminally modified rna
|
WO2014099984A1
(en)
|
2012-12-20 |
2014-06-26 |
Amgen Inc. |
Apj receptor agonists and uses thereof
|
TW201446792A
(en)
|
2013-03-12 |
2014-12-16 |
Amgen Inc |
Potent and selective inhibitors of Nav1.7
|
US10258698B2
(en)
|
2013-03-14 |
2019-04-16 |
Modernatx, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
TW201534726A
(en)
|
2013-07-03 |
2015-09-16 |
Halozyme Inc |
Thermally stable PH20 hyaluronidase variants and uses thereof
|
US9764039B2
(en)
|
2013-07-10 |
2017-09-19 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
AU2014315287A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
US20160194368A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
US10323076B2
(en)
|
2013-10-03 |
2019-06-18 |
Modernatx, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
ES2754397T3
(en)
|
2013-10-11 |
2020-04-17 |
Asana Biosciences Llc |
Protein-polymer-drug conjugates
|
US9840493B2
(en)
|
2013-10-11 |
2017-12-12 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
CA2926586C
(en)
|
2013-10-11 |
2020-04-07 |
Mersana Therapeutics, Inc. |
Polymeric scaffold based on phf for targeted drug delivery
|
US11103593B2
(en)
|
2013-10-15 |
2021-08-31 |
Seagen Inc. |
Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
|
MA39711A
(en)
|
2014-04-03 |
2015-10-08 |
Nektar Therapeutics |
Conjugates of an il-15 moiety and a polymer
|
US10941182B2
(en)
|
2014-06-10 |
2021-03-09 |
Amgen Inc. |
Apelin polypeptides
|
US20170204152A1
(en)
|
2014-07-16 |
2017-07-20 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
WO2016014846A1
(en)
|
2014-07-23 |
2016-01-28 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of intrabodies
|
PL3482766T3
(en)
|
2014-08-11 |
2020-11-16 |
Delinia, Inc. |
Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
TR201907471T4
(en)
|
2014-08-28 |
2019-06-21 |
Halozyme Inc |
Combination therapy with a hyaluronan degrading enzyme and an immune checkpoint inhibitor.
|
BR112017007765B1
(en)
|
2014-10-14 |
2023-10-03 |
Halozyme, Inc |
COMPOSITIONS OF ADENOSINE DEAMINASE-2 (ADA2), VARIANTS THEREOF AND METHODS OF USING THE SAME
|
ES2874331T3
(en)
|
2014-10-24 |
2021-11-04 |
Bristol Myers Squibb Co |
Modified FGF-21 Polypeptides and Uses Thereof
|
GB201419108D0
(en)
|
2014-10-27 |
2014-12-10 |
Glythera Ltd |
Materials and methods relating to linkers for use in antibody drug conjugates
|
JP2019501131A
(en)
|
2015-12-04 |
2019-01-17 |
シアトル ジェネティックス, インコーポレイテッド |
Complex of quaternized tubulysin compound
|
US11793880B2
(en)
|
2015-12-04 |
2023-10-24 |
Seagen Inc. |
Conjugates of quaternized tubulysin compounds
|
US20170204154A1
(en)
|
2016-01-20 |
2017-07-20 |
Delinia, Inc. |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
AU2017237186A1
(en)
|
2016-03-25 |
2018-11-01 |
Seagen Inc. |
Process for the preparation of PEGylated drug-linkers and intermediates thereof
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
MY193457A
(en)
|
2017-02-08 |
2022-10-14 |
Bristol Myers Squibb Co |
Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
|
US11730822B2
(en)
|
2017-03-24 |
2023-08-22 |
Seagen Inc. |
Process for the preparation of glucuronide drug-linkers and intermediates thereof
|
SG11201912071QA
(en)
|
2017-06-22 |
2020-01-30 |
Catalyst Biosciences Inc |
Modified membrane type serine protease 1 (mtsp-1) polypeptides and methods of use
|
KR102020995B1
(en)
|
2017-10-30 |
2019-09-16 |
한국코러스 주식회사 |
A method of preparing gcsf and polyol_conjugated conjugates with high yield
|
WO2019222435A1
(en)
|
2018-05-16 |
2019-11-21 |
Halozyme, Inc. |
Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
|
MX2021002301A
(en)
|
2018-08-28 |
2021-04-28 |
Ambrx Inc |
Anti-cd3 antibody folate bioconjugates and their uses.
|
HRP20240016T1
(en)
|
2018-09-11 |
2024-03-29 |
Ambrx, Inc. |
Interleukin-2 polypeptide conjugates and their uses
|
AU2019361206A1
(en)
|
2018-10-19 |
2021-06-03 |
Ambrx, Inc. |
Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
|
US11613744B2
(en)
|
2018-12-28 |
2023-03-28 |
Vertex Pharmaceuticals Incorporated |
Modified urokinase-type plasminogen activator polypeptides and methods of use
|
JP2022516725A
(en)
|
2018-12-28 |
2022-03-02 |
カタリスト・バイオサイエンシーズ・インコーポレイテッド |
Modified urokinase-type plasminogen activator polypeptide and usage
|
EP3923991A1
(en)
|
2019-02-12 |
2021-12-22 |
Ambrx, Inc. |
Compositions containing, methods and uses of antibody-tlr agonist conjugates
|
WO2021173889A1
(en)
|
2020-02-26 |
2021-09-02 |
Ambrx, Inc. |
Uses of anti-cd3 antibody folate bioconjugates
|
EP4117732A1
(en)
|
2020-03-11 |
2023-01-18 |
Ambrx, Inc. |
Interleukin-2 polypeptide conjugates and methods of use thereof
|
EP3954393A1
(en)
|
2020-08-13 |
2022-02-16 |
Bioasis Technologies Inc. |
Combination therapies for delivery across the blood brain barrier
|
JP2023538071A
(en)
|
2020-08-20 |
2023-09-06 |
アンブルックス,インコーポレイテッド |
Antibody-TLR agonist conjugates, methods and uses thereof
|
CA3213805A1
(en)
|
2021-04-03 |
2022-10-06 |
Feng Tian |
Anti-her2 antibody-drug conjugates and uses thereof
|